Prophylaxis of skeletal events in patients w/ breast cancer and bone metastases: 50 mg/day.
Treatment and prophylaxis of postmenopausal osteoporosis: 150 mg once mthly on the same date each mth, or 2.5 mg/day.
Hypercalcaemia of malignancy: 2-4 mg as a single infusion. Max: 6 mg.
Postmenopausal osteoporosis: 3 mg by inj once every 3 mth.
Prophylaxis of skeletal events in patients w/ breast cancer and bone metastases: 6 mg by infusion 3-4 wkly.
Adverse drug reactions
: flu-like symptoms (e.g. myalgia, arthralgia, fever, chills, fatigue, nausea, loss of appetite, bone pain), atypical fractures, osteonecrosis of the jaw, ocular inflammation, acute renal failure, hypocalcaemia, musculoskeletal pain.
Adapted from CIMS Drug Information System. Internet. Accessed on January 10, 2016.